OBJECTIVES: We examined the effects of the flavanol (-)-epicatechin on short- and long-term infarct size and left ventricular (LV) structure and function after permanent coronary occlusion (PCO) and the potential involvement of the protective protein kinase B (AKT)/extracellular signal-related kinase (ERK) signaling pathways. BACKGROUND: (-)-epicatechin reduces blood pressure in hypertensive patients and limits infarct size in animal models of myocardial ischemia-reperfusion injury. However, nothing is known about its effects on infarction after PCO. METHODS: (-)-epicatechin (1 mg/kg daily) treatment was administered via oral gavage to 250 g male rats for 10 days before PCO and was continued afterward. The PCO controls received water. Sham animals underwent thoracotomy and treatment in the absence of PCO. Immunoblots assessed AKT/ERK involvement 2 h after PCO. The LV morphometric features and function were measured 48 h and 3 weeks after PCO. RESULTS: In the 48-h group, treatment reduced infarct size by 52%. There were no differences in hemodynamics among the different groups (heart rate and aortic and LV pressures). Western blots revealed no differences in AKT or ERK phosphorylation levels. At 3 weeks, PCO control animals demonstrated significant increases in LV end-diastolic pressure, heart and body weight, and LV chamber diameter versus sham. The PCO plus (-)-epicatechin group values were comparable with those of the sham plus (-)-epicatechin group. Treatment resulted in a 33% decrease in myocardial infarction size. The LV pressure-volume curves demonstrated a right shift in control PCO animals, whereas the (-)-epicatechin curves were comparable with those of the sham group. The LV scar area strains were significantly improved with (-)-epicatechin. CONCLUSIONS: These results demonstrate the unique capacity of (-)-epicatechin to confer cardioprotection in the setting of a severe form of myocardial ischemic injury. Protection is sustained over time and preserves LV structure and function. The cardioprotective mechanism(s) of (-)-epicatechin seem to be unrelated to AKT or ERK activation. (-)-epicatechin warrants further investigation as a cardioprotectant. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: We examined the effects of the flavanol(-)-epicatechin on short- and long-term infarct size and left ventricular (LV) structure and function after permanent coronary occlusion (PCO) and the potential involvement of the protective protein kinase B (AKT)/extracellular signal-related kinase (ERK) signaling pathways. BACKGROUND:(-)-epicatechin reduces blood pressure in hypertensivepatients and limits infarct size in animal models of myocardial ischemia-reperfusion injury. However, nothing is known about its effects on infarction after PCO. METHODS:(-)-epicatechin (1 mg/kg daily) treatment was administered via oral gavage to 250 g male rats for 10 days before PCO and was continued afterward. The PCO controls received water. Sham animals underwent thoracotomy and treatment in the absence of PCO. Immunoblots assessed AKT/ERK involvement 2 h after PCO. The LV morphometric features and function were measured 48 h and 3 weeks after PCO. RESULTS: In the 48-h group, treatment reduced infarct size by 52%. There were no differences in hemodynamics among the different groups (heart rate and aortic and LV pressures). Western blots revealed no differences in AKT or ERK phosphorylation levels. At 3 weeks, PCO control animals demonstrated significant increases in LV end-diastolic pressure, heart and body weight, and LV chamber diameter versus sham. The PCO plus (-)-epicatechin group values were comparable with those of the sham plus (-)-epicatechin group. Treatment resulted in a 33% decrease in myocardial infarction size. The LV pressure-volume curves demonstrated a right shift in control PCO animals, whereas the (-)-epicatechin curves were comparable with those of the sham group. The LV scar area strains were significantly improved with (-)-epicatechin. CONCLUSIONS: These results demonstrate the unique capacity of (-)-epicatechin to confer cardioprotection in the setting of a severe form of myocardial ischemic injury. Protection is sustained over time and preserves LV structure and function. The cardioprotective mechanism(s) of (-)-epicatechin seem to be unrelated to AKT or ERK activation. (-)-epicatechin warrants further investigation as a cardioprotectant. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: R J Nijveldt; E van Nood; D E van Hoorn; P G Boelens; K van Norren; P A van Leeuwen Journal: Am J Clin Nutr Date: 2001-10 Impact factor: 7.045
Authors: Elena Cienfuegos-Jovellanos; María del Mar Quiñones; Begoña Muguerza; Leila Moulay; Marta Miguel; Amaya Aleixandre Journal: J Agric Food Chem Date: 2009-07-22 Impact factor: 5.279
Authors: M G Hertog; D Kromhout; C Aravanis; H Blackburn; R Buzina; F Fidanza; S Giampaoli; A Jansen; A Menotti; S Nedeljkovic Journal: Arch Intern Med Date: 1995-02-27
Authors: Hagen Schroeter; Parmvir Bahia; Jeremy P E Spencer; Olivia Sheppard; Marcus Rattray; Enrique Cadenas; Catherine Rice-Evans; Robert J Williams Journal: J Neurochem Date: 2007-02-07 Impact factor: 5.372
Authors: Christophe Depre; Song-Jung Kim; Anna S John; Yanhong Huang; Ornella E Rimoldi; John R Pepper; Gilles D Dreyfus; Vinciane Gaussin; Dudley J Pennell; Dorothy E Vatner; Paolo G Camici; Stephen F Vatner Journal: Circ Res Date: 2004-07-08 Impact factor: 17.367
Authors: Katrina Go Yamazaki; Aleksander Y Andreyev; Pilar Ortiz-Vilchis; Susanna Petrosyan; Ajit S Divakaruni; Sandra E Wiley; Christine De La Fuente; Guy Perkins; Guillermo Ceballos; Francisco Villarreal; Anne N Murphy Journal: Int J Cardiol Date: 2014-05-15 Impact factor: 4.164
Authors: Katsuyuki Tanabe; Yoshifuru Tamura; Miguel A Lanaspa; Makoto Miyazaki; Norihiko Suzuki; Waichi Sato; Yohei Maeshima; George F Schreiner; Francisco J Villarreal; Richard J Johnson; Takahiko Nakagawa Journal: Am J Physiol Renal Physiol Date: 2012-08-29
Authors: Aldo Moreno-Ulloa; Armando Cid; Ivan Rubio-Gayosso; Guillermo Ceballos; Francisco Villarreal; Israel Ramirez-Sanchez Journal: Bioorg Med Chem Lett Date: 2013-06-01 Impact factor: 2.823
Authors: Maik Hüttemann; Icksoo Lee; Guy A Perkins; Steven L Britton; Lauren G Koch; Moh H Malek Journal: Clin Sci (Lond) Date: 2013-06 Impact factor: 6.124